BioMAP® Primary Human Cell Systems for Improving Drug Discovery and Development

BioMAP® Primary Human Cell Systems for Improving Drug Discovery and Development
Version:
v122014

File Name/Number:
SLAS2014

Year:
2014

Improving the safety of drug candidates that enter clinical development requires assays that are more predictive of human outcomes. The BioMAP platform uses human primary cells to model complex aspects of disease and  tissue biology and can be applied to better understand biological mechanisms that underlie drug efficacy and  safety. Here we test Ibrutinib, a BTK inhibitor recently approved by the US FDA for B-cell malignancies, for activities in a broad range of human biology by profiling in the Diversity PLUS® panel of 12 BioMAP systems, and comparing the profile of Ibrutinib to a highly selective BTK inhibitor, GDC-0834, and to other reference compounds in the  BioMAP database.